PMID- 35884547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220731
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 14
DP  - 2022 Jul 18
TI  - Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle 
      against Cancer.
LID - 10.3390/cancers14143487 [doi]
LID - 3487
AB  - Dihydromyricetin (DHM) is a natural flavonoid compound extracted from Ampelopsis 
      grossedentata that has been used for centuries in traditional Chinese medicine. 
      DHM has attracted intensive attention due to its numerous beneficial activities, 
      such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. 
      In addition, DHM inhibits the progression of cancers such as lung cancer, 
      hepatocellular cancer, breast cancer, melanoma, and malignant reproductive 
      systems through multiple mechanisms, including antiangiogenesis, 
      antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, 
      DHM also activates autophagy at different levels, exerting a dual-regulatory 
      effect on cancers. Mechanistically, DHM can effectively regulate mammalian target 
      of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 
      3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-kappaB (NF-kappaB), p53, 
      and endoplasmic reticulum stress (ER stress)-driven signaling in different types 
      of cancers. DHM has also been shown to have inhibitory effects on various 
      regulators that trigger epithelial-mesenchymal transition (EMT). Furthermore, DHM 
      exhibits a remarkable anticancer reversal ability when used in combination with 
      drugs such as adriamycin, nedaplatin, and other drugs. However, the low 
      bioavailability of DHM limits its potential applications, which are improved 
      through structural modification and the exploration of novel dosage forms. 
      Therefore, DHM may become a promising candidate for treating malignancies alone 
      or combined with conventional anticancer strategies used in clinical practice.
FAU - Wu, Jiajun
AU  - Wu J
AD  - Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, 
      School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
FAU - Xiao, Zuowei
AU  - Xiao Z
AD  - Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, 
      School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
FAU - Li, Hongfang
AU  - Li H
AD  - Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, 
      School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
FAU - Zhu, Neng
AU  - Zhu N
AD  - Department of Urology, The First Hospital of Hunan University of Chinese 
      Medicine, Changsha 410208, China.
FAU - Gu, Jia
AU  - Gu J
AD  - Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, 
      School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
FAU - Wang, Wenmao
AU  - Wang W
AD  - Zhangjiajie Meicha Technology Research Center, Hunan Qiankun Biotechnology Co., 
      Ltd., Zhangjiajie 427000, China.
FAU - Liu, Chao
AU  - Liu C
AD  - Zhangjiajie Meicha Technology Research Center, Hunan Qiankun Biotechnology Co., 
      Ltd., Zhangjiajie 427000, China.
FAU - Wang, Wei
AU  - Wang W
AUID- ORCID: 0000-0003-0876-2205
AD  - TCM and Ethnomedicine Innovation & Development International Laboratory, School 
      of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
FAU - Qin, Li
AU  - Qin L
AUID- ORCID: 0000-0002-9797-2636
AD  - Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, 
      School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
AD  - Institutional Key Laboratory of Vascular Biology and Translational Medicine in 
      Hunan Province, Hunan University of Chinese Medicine, Changsha 410208, China.
AD  - Hunan Engineering Technology Research Center for Bioactive Substance Discovery of 
      Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
LA  - eng
GR  - 81973668/National Natural Sciences Foundation of China/
GR  - 81774130/National Natural Sciences Foundation of China/
GR  - 20A375/the Key Project of the Educational Department of Hunan Province/
GR  - kq2004060/the Scientific Research Project of Changsha Science and Technology 
      Bureau/
GR  - 202213055529/Key Project of Hunan Provincial Health Commission/
GR  - na/the First-Class Discipline of Pharmaceutical Science of Hunan; Special 
      Scientific and Technologi-cal Project for Comprehensive Utilization of Ampelopsis 
      grossedentata Resources of Hunan Qi-ankun Biotechnology Co., Ltd./
PT  - Journal Article
PT  - Review
DEP - 20220718
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9317349
OTO - NOTNLM
OT  - anticancer activity
OT  - dihydromyricetin
OT  - multidrug resistance
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/07/18
CRDT- 2022/07/27 01:10
PHST- 2022/05/13 00:00 [received]
PHST- 2022/07/09 00:00 [revised]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2022/07/27 01:10 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/07/18 00:00 [pmc-release]
AID - cancers14143487 [pii]
AID - cancers-14-03487 [pii]
AID - 10.3390/cancers14143487 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Jul 18;14(14):3487. doi: 10.3390/cancers14143487.